Chemomab Therapeutics Ltd.
Cash Flow Statement
| Line Item | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-8.8M | $-8.3M | $-8.1M | $-6.2M | $-5.1M | $-5.0M | $-3.0M | $-2.8M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $16.0K | $14.0K | $17.0K | $14.0K | $13.0K | $11.0K | $9.0K | $7.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $484.0K | $740.0K | $836.0K | $761.0K | $874.0K | $1.0M | $441.0K | $527.0K |
| Net Cash from Operating Activities | $-7.2M | $-5.7M | $-5.3M | $-5.7M | $-3.7M | $-2.9M | $-2.6M | $-5.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.0K | $1.0K | $42.0K | $11.0K | $14.0K | $134.0K | $0 | $102.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $14.4M | $9.4M | $6.1M | $1.7M | $2.4M | $-19.6M | $-5.0M | $-20.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $0 | $-869.0K | $39.0K | $22.0K | $0 | $-81.0K | $-72.0K | $13.4M |
| Net Change in Cash | $7.2M | $2.8M | $858.0K | $-4.0M | $-1.3M | $-22.6M | $-7.7M | $-12.8M |
| Free Cash Flow | $-7.2M | $-5.7M | $-5.3M | $-5.7M | $-3.7M | $-3.0M | $-2.6M | $-5.7M |